This study is looking at how safe and well-tolerated a drug called [18F]LY4214835 is when given intravenously (into a vein). It's being tested in both healthy volunteers and people with cancer. The researchers want to see if there are any side effects and how the body handles the drug, specifically how much radiation is absorbed by different organs. This study is for adults aged 18 and older. If you have cancer, you might be able to join if your cancer has been confirmed and you haven't had systemic cancer treatment yet, or if your current treatment isn't working. You would also need to have at least one tumor that is 15 millimeters (mm) or larger. The study is currently unclear on its recruitment status.

Study design

This is an interventional study planning to enroll 41 participants, including both healthy volunteers and individuals with cancer.

What's involved

Your participation in the study will last approximately 35 days. The study drug, [18F]LY4214835, will be given intravenously (IV).

Compensation

Not stated in the trial record.

Follow-up

Researchers will monitor for adverse events and radiation absorbed dose estimates from baseline through Day 3.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.